Lilly’s Cialis gets European endorsement for new use

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

 A European committee has endorsed the use of Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied to an enlarged prostate.

The European Union's Committee for Medicinal Products for Human Use recommended approval of a 5-milligram dose of Cialis for patients with benign prostatic hyperplasia. The European Commission usually decides on the committee's opinion within a month or two, Lilly said Friday. It doesn't have to follow the recommendation but often does.

Benign prostatic hyperplasia, or an enlarged prostate, can cause symptoms like the need to urinate urgently and frequently.

The U.S. Food and Drug Administration approved Cialis last fall for the treatment of symptoms of an enlarged prostate. Regulators also have approved this use in Canada, Mexico and Brazil, among other countries.

Cialis brought in $1.88 billion last year, or 8 percent of Lilly's total revenue, as its fifth-best-selling product.

Shares of the Indianapolis drugmaker closed at $47.46 after rising as high as $47.71 earlier in the day, its highest level in four years.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In